Two unverified FDA adverse event reports link deaths to products sold as retatrutide, an investigational compound that is not FDA approved. Here is what the reports say, what they do not prove, and how research labs should verify material before it reaches the bench.
New Bill Would Direct the VA to Study Peptide Therapies for Veterans
On September 1, 2026, Rep. Nancy Mace introduced the PEPTIDES for Veterans Act, a bill directing the Department of Veterans Affairs to formally study peptide-based therapies for veterans receiving VA care. Here's what the bill actually does, and doesn't do, for the research community.
What the Bill Actually Does
This is a notably different kind of peptide story than the FDA compounding debate that has dominated headlines this year. It's a legislative proposal focused specifically on how the VA health system evaluates and potentially adopts peptide-based treatments.
Under the bill, the VA Secretary would first have to complete a review of existing regulations and guidance related to peptides and report back to Congress within 180 days of the bill becoming law. From there, the VA would conduct an 18-month study looking at whether peptide-based therapies show measurable safety and efficacy for issues like recovery, rehabilitation, chronic pain, and mental health support tied to service-connected conditions.
If that study concludes the therapies are safe and beneficial, the legislation calls for a voluntary VA pilot program, allowing the agency to track real-world outcomes before considering any broader rollout across VA medical facilities. Rep. Mace framed the bill as a way to cut through bureaucratic delay, saying VA policy should "study it, test it, follow the evidence."
It's worth noting this bill does not change any current law. Peptides remain subject to existing FDA rules regardless of this legislation, and any VA program described here is contingent on the outcome of a study that hasn't started yet.
Frequently Asked Questions
Does this bill make any peptides legal or FDA-approved? No. The bill only directs the VA to study peptide therapies; it doesn't alter FDA approval status or legality of any specific compound.
How long would the process take? The VA has 180 days just to report on existing regulations, followed by an 18-month study before any pilot program could even be considered.
Who would be eligible for the potential pilot program? The bill describes a voluntary program for veterans receiving care through the VA, contingent on the study findings.
Is this bill law yet? No. As of this writing it has just been introduced in the House and would need to pass through the standard legislative process.
Where can I read the original announcement? The full press release is available on Rep. Mace's official House website.










